This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Case study: Christine from the EMBED trial tells us how just a small amount of her time could have a big impact on those with a breast cancer diagnosis in the future

A small amount of time could make a big difference

Christine from Portsmouth is taking part in the EMBED trial which tests adding in an extra blood test into the surveillance of ladies who are at increased risk of developing breast cancer. This might be because of a strong family history, or because they have had a previous occurrence of breast cancer themselves. Participants are already on yearly mammogram screening instead of the more usual 3-yearly screening programme.

This study is  ‘testing the test’, so it may be that if proven to be effective, the blood test will become a part of the screening/surveillance for this population of ladies.

What led you to take part in the EMBED study?

Following a breast cancer diagnosis in 2019 my treatment included surgery, radiotherapy, chemotherapy then regular scans and mammograms. I was asked to take part in the study alongside my regular mammogram checks. As I am a firm believer that research is vital to further improve treatment and good outcomes, I said 'yes' straightaway. 

What is your experience of the study so far?

So far,  I have provided information on my background, going back many years, and have provided a blood sample. The process so far has been absolutely fine. The research team are very nice, friendly,  professional,  readily explaining anything I didn't understand, supportive and kind. I am feeling well and at 73,  hope to have many more years of enjoyment and good health. I believe that clinical trials like this one will inform future research and lead to even better treatment in the future. To anyone who is thinking of taking part in a research trial, I would say absolutely, please take part. It is a good feeling that the small amount of time required of participants could have a significant and beneficial impact on those who are diagnosed in the future.